The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effects of long-term rifampicin administration in primary biliary cirrhosis
Open accessAbstract
The effects of rifampicin treatment (10 mg.kg-1.day-1) on pruritus and cholestasis were evaluated in 16 patients with primary biliary cirrhosis and pruritus followed up for 2-24 months. Assessment of pruritus severity, liver tests, aminopyrine breath test, and bile acids was done at 2 weeks and every 3 months after the beginning of the study. Two patients (12.5%) were withdrawn after 2 months of treatment because they had hepatitis caused by rifampicin. Four patients were withdrawn after 4 months because of liver transplantation (3 cases) and the development of leg edema associated with administration of rifampicin. The remaining 10 patients received therapy for 14.4 +/- 0.7 months and did not experience side effects. Pruritus improved in all patients and disappeared in 11 patients (79%) after 3 months of treatment. Moreover, all patients followed up for more than 1 year were free of pruritus. The alkaline phosphatase level decreased significantly, and the aminopyrine breath test results increased significantly after 2 weeks of treatment (P less than 0.001) and did not change thereafter. In the 9 patients treated for 15 months, alkaline phosphatase levels decreased to 63% of the basal levels and aminopyrine breath test results increased to 153% of baseline values. Transaminases, gamma-glutamyltransferase, and total bile salt levels decreased significantly after 2 weeks of treatment but returned to baseline after 3 months. No changes in bilirubin and cholesterol levels were observed. It is concluded that long-term rifampicin treatment is effective for relieving pruritus in primary biliary cirrhosis, but liver enzymes should be monitored to detect drug-induced hepatitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several prospective randomised placebo-controlled trials have shown rifampicin to be effective in the management of cholestatic pruritus.182–185”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [185]
Citations
Cites
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?
Poupon, R. Y., Poupon, R., Calmus, Y., Chrétien, Y., Ballet, F., & Darnis, F. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91610-2 · Cited by 534
The presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504
Christensen, E., Crowe, J., Doniach, D., Pópper, H., Ranek, L., Rodés, J., Tygstrup, N., & Williams, R. L. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90571-5 · Cited by 271
Self-citationTreatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231
Self-citationRelief of the Pruritus of Jaundice with a Bile-Acid Sequestering Resin
Carey, J. B. (1961) · JAMA · doi:10.1001/jama.1961.03040180034008 · Cited by 134
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120
Rifampin relieves pruritus in children with cholestatic liver disease
Cynamon, H. A., Andres, J. M., & Iafrate, R. P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90027-x · Cited by 109
Research works printed but not linked: 2
- Pérez-Ayuso, 1980, Effect of phenobarbital treatment on pruritus and hepatic excretory function in primary biliary cirrhosis (abstr), Gastroenterology, 79, 1119
- Quintero, 1986, Utilidad del recambio plasmático intermitente en la cirrosis biliar primaria, Gastroenterol Hepatol, 9, 329
Cited by
Sorted by citations
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy
Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1666st · Cited by 1,216
A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR
Urizar, N. L., Liverman, A. D. B., Dodds, D. T., Silva, F. V., Ordentlich, P., Yan, Y. G., Gonzalez, F. J., Heyman, R. A., Mangelsdorf, D. J., & Moore, D. D. (2002) · Science · doi:10.1126/science.1072891 · Cited by 553
Metadata
- Authors
- Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- ORCID
- Parés, Albert
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1992-06
- Volume
- 102
- Issue
- 6
- Pages
- 2077-2080
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1219313770
- Cited by
- 235
- References
- 24
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 7 · 2015: 12 · 2014: 8 · 2013: 5 · 2012: 7
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- rifampicin, primary biliary cirrhosis, pruritus, cholestasis, drug-induced hepatitis, aminopyrine breath test, alkaline phosphatase, bile acids, long-term drug therapy, adverse drug reactions
- MeSH terms
- Bile Acids and Salts, Cholestasis, Female, Humans, Liver, Liver Cirrhosis, Biliary, Middle Aged, Pruritus, Rifampin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
